

1

2

3 **Refractive errors, ocular biometry and diabetic retinopathy: a systematic review**

4

5

6 Miao He, MD PhD¹, Haiying Chen, MD², Wei Wang, MD PhD³

7

8

9 1. Department of Ophthalmology, Guangdong General Hospital, Guangdong

10 Academy of Medical Sciences, Guangzhou, People's Republic of China.

11 2. The Royal Melbourne Hospital, Melbourne, Victoria, Australia.

12 3. Zhongshan Ophthalmic Center, State Key Laboratory of Ophthalmology, Sun

13 Yat-Sen University, Guangzhou, People's Republic of China.

14

15

16 **Corresponding author:** Wei Wang, MD, PhD, Zhongshan Ophthalmic Center, State

17 Key Laboratory of Ophthalmology, Sun Yat-sen University

18 54S.Xianlie Road, Guangzhou, China 510060

19 Email: zoc_wangwei@yahoo.com

20

21 **ABSTRACT**

22 Diabetic retinopathy (DR) is one of the major causes of visual impairment and
23 blindness worldwide. The onset and progression of DR are influenced by systemic
24 factors such as hyperglycemia and hypertension as well as ocular parameters. A
25 better knowledge of the risk factors for DR is vital to improving the outcome of
26 patients with DR and risk stratification. More recently, there has been increasing
27 focus on the influence of myopia on DR development. Some observational studies
28 have reported myopia being a protective factor for the development of DR, however
29 the findings were inconsistent. In addition, it remains unclear whether it was myopia,
30 axial length (AL), or other refractive factors that play the protective role. The
31 protective mechanism against DR may be related to ocular elongation, posterior
32 vitreous detachment, low perfusion in the retina and the abnormal cytokine profile.
33 This systematic review will summarize the association of DR with refractory status as
34 well as different refractive components including anterior chamber depth, refractory
35 power of the lens, AL, and axial length-to-corneal radius ratio.

36

37 **Keywords:** Diabetic retinopathy; High myopia; Axial length; Ocular biometry

38

39 **1. Introduction**

40 While diabetic retinopathy (DR) is a common cause of blindness in middle-aged and
41 elderly patients, its pathogenesis remains unclear. Compared to the widely known
42 systemic risk factors such as the duration of DR, glycemic control, blood pressure,
43 research on ocular risk factors is limited.^{1; 2; 3} Myopia has emerged as a public
44 challenge worldwide. In particular, high myopia increases the risk of blindness
45 significantly due to its sight-threatening complications.⁴ It was estimated that half of
46 the world's population (5 billion) will develop myopia by 2050, and there will be one
47 fifth of the population (1 billion) with high myopia.⁵ In some East Asian area, high
48 myopia has become the leading cause of blindness.^{6; 7} The earliest study on the
49 association between myopia and DR onset dated back to 1960.⁸ Previous studies
50 have reported myopia as a protection factor for DR, however this was not widely
51 accepted.^{9; 10; 11} Clinical data suggested that those with high myopia have a smaller
52 risk for DR; in addition, it was less likely for diabetes patients with myopia to develop
53 severe DR. Small hospital-based studies and epidemiology studies showed that
54 myopia might be protective against DR, but the findings were inconsistent.^{12; 13} It
55 remains unclear whether ocular structure, refractive parameters, or both contribute
56 to this protective effect. Whether the protective effect of myopia against DR is
57 related to the refractive status itself or ocular biometrics, including anterior chamber
58 depth (ACD), corneal curvature, axial length (AL), axial length-to-corneal radius ratio
59 (AL/CR ratio) is yet to be determined.

60

61 **2. Refractive error and DR**

62 Previous studies that investigated the relationship between refractive errors and DR
63 were summarized in Table 1. In a clinical retrospective study of 19 participants with
64 38 eyes with asymmetric DR by Dogru and colleagues, there was zero case of
65 proliferative diabetic retinopathy (PDR) in eyes with high myopia and complete
66 posterior vitreous detachment (PVD).¹⁴ The group therefore proposed that high
67 myopia and complete PVD may delay the progression of PDR. However, the study
68 was based on a small sample size of 19 participants. Another study that evaluated

69 116 participants with anisometropia reported that after controlling for factors such
70 as age, diabetes duration, ethnicity etc., high myopia could delay the onset of DR,
71 and such protective effect was stronger with higher myopia.¹⁵
72 A number of population-based cross-sectional studies have investigated the
73 relationship between refractive status and DR. A Singaporean study reported a
74 reduced risk for DR, especially vision threatening DR (VTDR) in myopia.¹² Another
75 study in Korea, the Korea National Health and Nutrition Examination Survey
76 (KNHANES), showed that with every 1 diopter increase in spherical equivalent (SE),
77 there was a 30% higher incidence of DR.¹⁶ The Beijing Eye study also reported a 32%
78 reduction in the risk for DR in myopia.¹⁷ In a population-based cohort study of 1210
79 young diabetic patients, myopia delayed the progression from DR to PDR after
80 adjusting for other factors.¹⁸ On the other hand, the Singapore Indian Eye Study did
81 not demonstrate a correlation between refractive error and DR, or between
82 refractive error and VTDR.¹⁹ A more recent prospective cohort study also reached a
83 similar conclusion that the SE and refractive error status were not associated with DR
84 onset or progression.²⁰ A common limitation of these studies is that there was no
85 assessment of how myopia of different severity affects DR other than PDR.

86

87 **3. AL, axial length-to-corneal radius ratio and DR**

88 Table 2 presents the relationship between AL, axial length-to-corneal radius (AL/CR)
89 ratio and DR risk in different studies. A study that followed a group of Chinese
90 patients for over 10 years reported that AL was negatively correlated with the
91 development of PDR.²¹ In a study involving 630 eyes of 367 patients, Man et al.¹³
92 found that eyes with longer AL had lower risk for any DR and diabetic macular edema
93 (DME), and that longer AL served as a protection factor for DR and DME. In a cohort
94 with coexisting DME and cataract, the group with longer AL had better best corrected
95 visual acuity (BCVA) than the control group at 12 months post vitrectomy.²² Another
96 retrospective study on diabetes patients with anisometropia (interocular AL
97 difference of > 1mm) showed that eyes with longer AL and thinner choroid had
98 significantly lower incidence of PDR.²³

99

100 Nevertheless, the relationship between AL and DR might vary amongst different
101 ethnicities. In the Singapore Malay Eye Study (SiMES), every 1mm increase of AL was
102 associated with a decreased risk for any DR, mild DR, and VTDR by 14%, 20% and 37%,
103 respectively.¹² Similarly, the recent Kailuan Eye Study in northern China reported that
104 the odds of DR decreased by 19% for every 1mm increase in AL.²⁴ The Beijing Eye
105 Study also found that every 1mm increase in AL was associated with a reduced odds
106 of DR by 38%.²⁵ In the Singaporean Indian population, longer AL was negatively
107 associated with any DR, but not with VTDR.¹⁹ A population study of 2057 type 2
108 diabetes mellitus (T2DM) adults in China reported that the refractive power of the
109 lens, AL/CR ratio, ocular elongation may contribute to the protective role of AL
110 against DR.²⁶ Specifically, the group suggested that people with longer AL and bigger
111 AL/CR ratio were less likely to develop DR. On the other hand, the Singapore Malay
112 and Indian Eye Study which followed 840 diabetes patients for 6 years did not
113 demonstrate a relationship between AL or other ocular biometric parameters and
114 the risk of VTDR.²⁰ The Ural Eye and Medical Study, a population-based study in
115 Russia, also reported no correlation between AL and DR ($P=0.16$).²⁷ Long AL is an
116 indicator of axial myopia, and the rapidly expanding prevalence of myopia globally
117 may have a potential impact on the incidence and prevalence of DR. More
118 longitudinal studies involving various ethnicities are warranted.

119

120 **4. ACD, lens parameters, corneal curvature and DR**

121 There are fewer studies on the association between ACD, lens parameters and DR,
122 and the results have been inconsistent (Table 3). Jiang and colleagues found that
123 shallower ACD was associated with higher risk for DR onset and progression, as well
124 as DME.²⁸ In the Singapore Malay Eye Study (SiMES), every 1mm increase in ACD was
125 associated with a reduced risk of middle DR and VTDR by 68% and 86%,
126 respectively.¹² On the other hand, the Beijing Eye Study and a hospital-based study in
127 Australia found no association between ACD and DR.^{13; 25}

128

129 Studies on the relationship between lens parameters and DR have reached different
130 conclusions. One study reported that the increase in lens thickness was associated
131 with PDR in insulin-dependent diabetes patients.²⁹ He and colleagues showed that
132 higher refractive power of the lens was associated with a higher risk for DR,
133 suggesting that the refractive power of the lens and other refractive factors may play
134 a role in DR onset.²⁶ However, Wiemer's group did not demonstrate any association
135 between lens parameters and DR after adjusting for confounding factors.³⁰ The
136 inconsistent findings might be attributable to the differences in research
137 methodology. As such, the influence of ACD and lens parameters on DR warrants
138 further population-based studies of a large sample size.

139

140 **5. Fundus tessellation, peripapillary atrophy and DR**

141 Fundus tessellation is darkly pigmented choroid in the posterior retina, which is
142 commonly seen in eyes with myopia or age-related degeneration, and is an
143 important consideration in the diagnosis of retinal-choroidal degeneration.
144 Peripapillary atrophy (PPA), also known as disc crescent, is closely associated with
145 myopia.^{31; 32; 33} Fundus tessellation and PPA, the two common early signs of axial high
146 myopia, are present in 81%-98% and 90%-93% of highly myopic eyes, respectively.^{34;}
147 ³⁵ The prevalence of PPA is 15%-20% in the general population, and can be as high as
148 67% in some reports.^{36; 37} Only one study so far has investigated the correlation
149 between DR and these two signs. A cross-sectional analysis of 592 diabetes patients
150 in the Singapore Chinese Eye Study showed that the presence of PPA and fundus
151 tessellation in diabetic patients was correlated with a lower risk for DR, independent
152 of other diabetes risk factors, AL, or refractive error.³⁸

153

154 **6. Possible mechanisms of the protective effect**

155 Based on previous studies discussed in the earlier part of this report, myopic
156 refractive error and long AL may be protective factors against DR. Possible
157 mechanisms might be attributable to the regulating effect of the increase in AL,
158 posterior vitreous detachment, low blood flow perfusion in the retina, choroidal

159 thinning, and the alteration of cytokine profile.^{39; 40; 41; 42; 43; 44} While the exact
160 mechanisms of how myopia is protective against DR remain elusive, most of the
161 attention is placed on the pathological changes of the eyeball incurred by the
162 increasing AL during the progression of myopia.^{39; 40; 41}

163

164 **6.1 Decrease in blood flow volume:**

165 One theory proposes that as myopia progresses, the scleral wall is stretched,
166 resulting in distortion of the posterior retina and a reduction in blood flow in the
167 retina.⁴⁵ The reduction in blood flow volume would decrease the pressure to vessel
168 wall, which may reduce the risk for DR onset. This is consistent with the theory that
169 the increased retinal blood flow volume is a significant risk factor for non-PDR
170 developing into PDR, as the retinal blood flow volume is greater in the diabetes
171 group compared to the non-diabetes group.⁴⁵ Nevertheless, one study that used
172 Heidelberg Retinal Flowmeter to measure the blood flow in the capillaries did not
173 demonstrate the reduction of retinal capillary blood flow as a main protective factor
174 against DR.⁴⁰

175

176 **6.2 Change of blood flow dynamics:**

177 In high myopia, there are varying degrees of atrophy and degeneration in the retina
178 and choroid. As AL increases, retinal and choroidal tissues become thinner and
179 vascular diameter reduces.^{49; 50} This results in an increase in the trans-vessel pressure
180 and a decrease in blood flow in the retina. The reduction in retinal blood flow
181 perfusion not only reduces the physical stress to the retinal vascular wall, but also
182 dampens the biochemical damage of hyperglycemia in diabetes. Patients with high
183 myopia are more likely to develop aged-related degeneration in the retinal
184 microvascular beds before 40 years of age, whereas retinal vasculature
185 degeneration usually occurs in T2DM patients after 40. It is possible that retinal and
186 choroidal degeneration occurs earlier on in patients with T2DM and high myopia,
187 leading to lower retinal blood flow perfusion.^{3; 38} This may partially offset the damage
188 from high blood flow perfusion that tends to occur in DR. In addition, intraocular

189 pressure (IOP) of myopic patients increases as myopia progresses, and IOP of patients
190 with moderate myopia is higher compared to IOP of people without myopia.⁵¹
191 Therefore, with the same systolic blood pressure, perfusion pressure of the eye
192 decreases as IOP increases, which would to some extent influence the
193 hemodynamics in the retina, hence the onset and progression of DR in highly myopic
194 patients.

195

196 **6.3 Decrease in oxygen demand:**

197 In myopia, the demand of oxygen decreases as the posterior scleral extends and the
198 retina thins, which may to some extent alleviate the effect of hypoxia on the retina
199 due to diabetes. Jonas et al observed a reduction in vascular endothelial growth
200 factor (VEGF) concentration in the vitreous humor in eyes with long AL, an indication
201 of relatively lighter hypoxic effect on the retina.⁵² Man and colleagues analyzed the
202 multifocal macular electroretinogram (fm-ERG) and oxygen consumption in retinal
203 veins and arteries in a cohort of 50 healthy participants, and found that artery-vein
204 oxygen consumption and retinal function decreased as AL increased.³⁹ Hence, the
205 reduction in retinal oxygen consumption due to long AL may reduce the hypoxic
206 stress and the risk of DR in diabetes patients. In addition, there is reduced oxygen
207 demand when the function of the outer retina deteriorates in high myopia, and the
208 hypoxic stress on the retina is relieved as more oxygen is obtained from the thinner
209 choroid, which together may delay the onset or progression of DR. Therefore, due to
210 the reduced metabolism in the atrophied choroid and outer retina as well as by
211 enabling easier oxygen diffusion through the thinner retinal and choroidal tissues,
212 high myopia could serve as a protective factor against DR.

213

214 **6.4 Posterior vitreous detachment:**

215 Posterior vitreous detachment (PVD) occurs when AL increases but the vitreous body
216 fails to extend with the globe in highly myopic eyes. PVD and liquefaction of the
217 vitreous humor are common in highly myopic eyes, which disables the supporting
218 structure for neovascularization and allows for more oxygen absorption through the

219 liquefied vitreous humor and aqueous fluid.⁵³ As a result, hypoxia in the retina is
220 partially relieved and the micro-environment for neovascularization is altered. Other
221 studies also reported that the fiber scaffolds for neovascular proliferation in the
222 vitreous body disappeared and oxygen diffused more easily in the liquefied vitreous
223 humor in complete PVD, hence delaying the progression of NPDR to
224 neovascularization and PDR. Evidence also suggested that DR patients with complete
225 PVD had a significantly lower risk for neovascularization in the retina and the optic
226 disc.^{54; 55}

227

228 **6.5 Change in cytokine profile:**

229 Many cytokines are implicated in the pathogenesis of DR such as endothelial injury,
230 retinal proliferation and neovascularization. Dysregulation of VEGF, pigment
231 epithelium derived factor (PEDF), tumor necrosis factor (TNF), erythropoietin (EPO),
232 transforming growth factor beta (TFG- β), endothelin (ET-1) have been implicated in
233 both DR and high myopia.^{44; 52; 56; 57; 58} The altered expression of these cytokines in
234 myopia may have an effect on DR progression. A few studies recorded lower
235 concentrations of VEGF and EPO in the vitreous in highly myopic eyes, and proposed
236 that the reduced expression of VEGF and EPO might help to retard the DR
237 progression in highly myopic eyes.⁴² Another study found that the PEDF
238 concentration was lower in patients with high myopia than in control subjects, which
239 might be due to the degeneration of retinal ganglion cells and retinal pigment
240 epithelium that produce the PEDF.⁵⁹ In patients with diabetes, high myopia may have
241 an accommodative effect by altering the expression profile of certain cytokines which
242 are implicated in the onset and progression of DR.

243

244 **7. Conclusion**

245 There is increasing evidence suggesting that high myopia may be a protective factor
246 against the onset and progression of DR. However, due to the differences in study
247 methods as well as quality and statistical analyses, results from previous studies have
248 been inconsistent. To date, no consensus has been reached regarding the association

249 between myopia and DR. Robust evidence is lacking to elucidate the association
250 between AL, ACD, lens parameters, and the risk for DR. Many studies did not account
251 for confounding factors such as age, gender and glycemic control. Whether or not
252 retinal changes due to high myopia predate DR remains unclear. We also suggest
253 future research look into the underlying choroidal and retinal changes in high myopia,
254 and their implications on DR, as opposed to merely the association between ocular
255 biometrics in myopia and DR. DR is a complex pathological process where multiple
256 factors contribute collectively. Current studies suggest that the protecting effect of
257 myopia against DR could be related to the prolongation of AL, posterior vitreous
258 detachment, low retinal blood flow perfusion, choroidal thinning and the altered
259 expression of cytokines. The exact mechanisms of how myopia, AL and ocular
260 biometrics influence the onset and progression of DR are yet to be determined.
261 Further investigation into the protective and risk factors of DR will provide valuable
262 basis for potential new intervention and treatment options for DR.

263

264 **8. Methods of Literature Search**

265 Systematic search was conducted in electronic databases including Pubmed
266 (<http://www.ncbi.nlm.nih.gov/pubmed>) and Embase.com (<http://www.embase.com>).
267 The ARVO Meeting Abstracts (<http://www.iovs.org/search.dtl?arvomtsearch=true>)
268 were retrieved for additional studies. The following key words were used in the
269 search: myopia, refractive error, short sight, diabetic retinopathy, diabetic eye
270 disease, axial length, anterior chamber depth, corneal curvature, corneal radius, lens
271 thickness, lens power, refractive power of lens. All abstracts were reviewed and
272 appropriate studies were obtained in full for complete review. The references of
273 included studies and related reviews were screened for additional articles. Articles
274 written in English were included, and those written in languages other than English
275 were considered when English abstracts were available.

276

277

278 **Acknowledgments**

279 The authors declare no conflict of interest with respect to the topic and the content

280 of this manuscript. This study was supported by the National Natural Science

281 Foundation of China (81900866).

282

283

284

References:

285 1. Leasher JL, Bourne RR, Flaxman SR, et al.: Global Estimates on the Number of
286 People Blind or Visually Impaired by Diabetic Retinopathy: A Meta-analysis From
287 1990 to 2010. *Diabetes Care* 39:1643-1649, 2016

288 2. Yau JW, Rogers SL, Kawasaki R, et al.: Global prevalence and major risk factors of
289 diabetic retinopathy. *Diabetes Care* 35:556-564, 2012

290 3. Stitt AW, Curtis TM, Chen M, et al.: The progress in understanding and treatment
291 of diabetic retinopathy. *Prog Retin Eye Res* 51:156-186, 2016

292 4. Morgan IG, Ohno-Matsui K, Saw SM: Myopia. *Lancet* 379:1739-1748, 2012

293 5. Holden BA, Fricke TR, Wilson DA, et al.: Global Prevalence of Myopia and High
294 Myopia and Temporal Trends from 2000 through 2050. *Ophthalmology*
295 123:1036-1042, 2016

296 6. Liu HH, Xu L, Wang YX, et al.: Prevalence and progression of myopic retinopathy in
297 Chinese adults: the Beijing Eye Study. *Ophthalmology* 117:1763-1768, 2010

298 7. Wong YL, Sabanayagam C, Ding Y, et al.: Prevalence, Risk Factors, and Impact of
299 Myopic Macular Degeneration on Visual Impairment and Functioning Among Adults
300 in Singapore. *Invest Ophthalmol Vis Sci* 59:4603-4613, 2018

301 8. Jain IS, Luthra CL, Das T: Diabetic retinopathy and its relation to errors of
302 refraction. *Arch Ophthalmol* 77:59-60, 1967

303 9. Wang X, Tang L, Gao L, et al.: Myopia and diabetic retinopathy: A systematic
304 review and meta-analysis. *Diabetes Res Clin Pract* 111:1-9, 2016

305 10. Fu Y, Geng D, Liu H, Che H: Myopia and/or longer axial length are protective
306 against diabetic retinopathy: a meta-analysis. *Acta Ophthalmol* 94:346-352, 2016

307 11. Man RE, Sasongko MB, Wang JJ, Lamoureux EL: Association between myopia and
308 diabetic retinopathy: a review of observational findings and potential mechanisms.
309 *Clin Exp Ophthalmol* 41:293-301, 2013

310 12. Lim LS, Lamoureux E, Saw SM, et al.: Are myopic eyes less likely to have diabetic
311 retinopathy? *Ophthalmology* 117:524-530, 2010

312 13. Man RE, Sasongko MB, Sanmugasundram S, et al.: Longer axial length is
313 protective of diabetic retinopathy and macular edema. *Ophthalmology*
314 119:1754-1759, 2012

315 14. Dogru M, Inoue M, Nakamura M, Yamamoto M: Modifying factors related to
316 asymmetric diabetic retinopathy. *Eye (Lond)* 12 (Pt 6):929-933, 1998

317 15. Bazzazi N, Akbarzadeh S, Yavarikia M, et al.: HIGH MYOPIA AND DIABETIC
318 RETINOPATHY: A Contralateral Eye Study in Diabetic Patients With High Myopic
319 Anisometropia. *Retina* 37:1270-1276, 2017

320 16. Chao DL, Lin SC, Chen R, Lin SC: Myopia is Inversely Associated With the
321 Prevalence of Diabetic Retinopathy in the South Korean Population. *Am J*
322 *Ophthalmol* 172:39-44, 2016

323 17. Xu J, Xu L, Wang YX, et al.: Ten-year cumulative incidence of diabetic retinopathy.
324 The Beijing Eye Study 2001/2011. *PLoS One* 9:e111320, 2014

325 18. Moss SE, Klein R, Klein BE: Ocular factors in the incidence and progression of
326 diabetic retinopathy. *Ophthalmology* 101:77-83, 1994

- 327 19.Pan CW, Cheung CY, Aung T, et al.: Differential associations of myopia with major
328 age-related eye diseases: the Singapore Indian Eye Study. *Ophthalmology*
329 120:284-291, 2013
- 330 20.Man R, Gan A, Gupta P, et al.: Is Myopia Associated with the Incidence and
331 Progression of Diabetic Retinopathy? *Am J Ophthalmol* 208:226-233, 2019
- 332 21.Yang KJ, Sun CC, Ku WC, et al.: Axial length and proliferative diabetic retinopathy.
333 *Optom Vis Sci* 89:465-470, 2012
- 334 22.Wakabayashi Y, Kimura K, Muramatsu D, et al.: Axial length as a factor associated
335 with visual outcome after vitrectomy for diabetic macular edema. *Invest Ophthalmol*
336 *Vis Sci* 54:6834-6840, 2013
- 337 23.Kim DY, Song JH, Kim YJ, et al.: Asymmetric diabetic retinopathy progression in
338 patients with axial anisometropia. *Retina* 38:1809-1815, 2018
- 339 24.Wang Q, Wang YX, Wu SL, et al.: Ocular Axial Length and Diabetic Retinopathy:
340 The Kailuan Eye Study. *Invest Ophthalmol Vis Sci* 60:3689-3695, 2019
- 341 25.Xu L, Cao WF, Wang YX, et al.: Anterior chamber depth and chamber angle and
342 their associations with ocular and general parameters: the Beijing Eye Study. *Am J*
343 *Ophthalmol* 145:929-936, 2008
- 344 26.He J, Xu X, Zhu J, et al.: Lens Power, Axial Length-to-Corneal Radius Ratio, and
345 Association with Diabetic Retinopathy in the Adult Population with Type 2 Diabetes.
346 *Ophthalmology* 124:326-335, 2017
- 347 27.Bikbov MM, Kazakbaeva GM, Gilmanshin TR, et al.: Axial length and its
348 associations in a Russian population: The Ural Eye and Medical Study. *PLoS One*
349 14:e211186, 2019
- 350 28.Jiang JJ, Li XX, Yuan L, et al.: Ocular biological structures and relevant risk factors
351 in the occurrence of diabetic retinopathy in diabetes mellitus patients. *Zhonghua Yan*
352 *Ke Za Zhi* 48:898-902, 2012
- 353 29.Pierro L, Brancato R, Zaganelli E, et al.: Correlation of lens thickness with blood
354 glucose control in diabetes mellitus. *Acta Ophthalmol Scand* 74:539-541, 1996
- 355 30.Wiemer NG, Dubbelman M, Kostense PJ, et al.: The influence of diabetes mellitus
356 type 1 and 2 on the thickness, shape, and equivalent refractive index of the human
357 crystalline lens. *Ophthalmology* 115:1679-1686, 2008
- 358 31.Ruiz-Medrano J, Montero JA, Flores-Moreno I, et al.: Myopic maculopathy:
359 Current status and proposal for a new classification and grading system (ATN). *Prog*
360 *Retin Eye Res* 69:80-115, 2019
- 361 32.Yokoi T, Jonas JB, Shimada N, et al.: Peripapillary Diffuse Chorioretinal Atrophy in
362 Children as a Sign of Eventual Pathologic Myopia in Adults. *Ophthalmology*
363 123:1783-1787, 2016
- 364 33.Ohno-Matsui K, Kawasaki R, Jonas JB, et al.: International photographic
365 classification and grading system for myopic maculopathy. *Am J Ophthalmol*
366 159:877-883, 2015
- 367 34.Yan YN, Wang YX, Xu L, et al.: Fundus Tessellation: Prevalence and Associated
368 Factors: The Beijing Eye Study 2011. *Ophthalmology* 122:1873-1880, 2015
- 369 35.Guo Y, Liu L, Zheng D, et al.: Prevalence and Associations of Fundus Tessellation
370 Among Junior Students From Greater Beijing. *Invest Ophthalmol Vis Sci*

- 371 60:4033-4040, 2019
- 372 36.Zhang Q, Wang YX, Wei WB, et al.: Parapapillary Beta Zone and Gamma Zone in a
373 Healthy Population: The Beijing Eye Study 2011. *Invest Ophthalmol Vis Sci*
374 59:3320-3329, 2018
- 375 37.Skaat A, De Moraes CG, Bowd C, et al.: African Descent and Glaucoma Evaluation
376 Study (ADAGES): Racial Differences in Optic Disc Hemorrhage and Beta-Zone
377 Parapapillary Atrophy. *Ophthalmology* 123:1476-1483, 2016
- 378 38.Tan N, Tham YC, Ding Y, et al.: Associations of Peripapillary Atrophy and Fundus
379 Tessellation with Diabetic Retinopathy. *Ophthalmol Retina* 2:574-581, 2018
- 380 39.Man RE, Lamoureux EL, Taouk Y, et al.: Axial length, retinal function, and oxygen
381 consumption: a potential mechanism for a lower risk of diabetic retinopathy in
382 longer eyes. *Invest Ophthalmol Vis Sci* 54:7691-7698, 2013
- 383 40.Man RE, Sasongko MB, Xie J, et al.: Decreased retinal capillary flow is not a
384 mediator of the protective myopia-diabetic retinopathy relationship. *Invest*
385 *Ophthalmol Vis Sci* 55:6901-6907, 2014
- 386 41.Bartol-Puyal FA, Isanta C, Ruiz-Moreno O, et al.: Distribution of Choroidal Thinning
387 in High Myopia, Diabetes Mellitus, and Aging: A Swept-Source OCT Study. *J*
388 *Ophthalmol* 2019:3567813, 2019
- 389 42.Kwon SH, Shin JP, Kim IT, Park DH: Aqueous Levels of Angiopoietin-like 4 and
390 Semaphorin 3E Correlate with Nonperfusion Area and Macular Volume in Diabetic
391 Retinopathy. *Ophthalmology* 122:968-975, 2015
- 392 43.Finzi A, Cellini M, Strobbe E, Campos EC: ET-1 plasma levels, choroidal thickness
393 and multifocal electroretinogram in retinitis pigmentosa. *Life Sci* 118:386-390, 2014
- 394 44.Jain A, Saxena S, Khanna VK, et al.: Status of serum VEGF and ICAM-1 and its
395 association with external limiting membrane and inner segment-outer segment
396 junction disruption in type 2 diabetes mellitus. *Mol Vis* 19:1760-1768, 2013
- 397 45.Ohno-Matsui K, Jonas JB: Posterior staphyloma in pathologic myopia. *Prog Retin*
398 *Eye Res* 70:99-109, 2019
- 399 46.Sun Z, Tang F, Wong R, et al.: OCT Angiography Metrics Predict Progression of
400 Diabetic Retinopathy and Development of Diabetic Macular Edema: A Prospective
401 Study. *Ophthalmology* 126:1675-1684, 2019
- 402 47.Hwang TS, Gao SS, Liu L, et al.: Automated Quantification of Capillary
403 Nonperfusion Using Optical Coherence Tomography Angiography in Diabetic
404 Retinopathy. *JAMA Ophthalmol* 134:367-373, 2016
- 405 48.Samara WA, Shahlaee A, Adam MK, et al.: Quantification of Diabetic Macular
406 Ischemia Using Optical Coherence Tomography Angiography and Its Relationship
407 with Visual Acuity. *Ophthalmology* 124:235-244, 2017
- 408 49.Li M, Yang Y, Jiang H, et al.: Retinal Microvascular Network and Microcirculation
409 Assessments in High Myopia. *Am J Ophthalmol* 174:56-67, 2017
- 410 50.Yang Y, Wang J, Jiang H, et al.: Retinal Microvasculature Alteration in High Myopia.
411 *Invest Ophthalmol Vis Sci* 57:6020-6030, 2016
- 412 51.Jonas JB, Nagaoka N, Fang YX, et al.: Intraocular Pressure and Glaucomatous Optic
413 Neuropathy in High Myopia. *Invest Ophthalmol Vis Sci* 58:5897-5906, 2017
- 414 52.Jonas JB, Tao Y, Neumaier M, Findeisen P: VEGF and refractive error.

415 Ophthalmology 117:2231-2234, 2010
416 53.Akiba J: Prevalence of posterior vitreous detachment in high myopia.
417 Ophthalmology 100:1384-1388, 1993
418 54.Anderson W, Piggott K, Bao YK, et al.: Complete Posterior Vitreous Detachment
419 Reduces the Need for Treatment of Diabetic Macular Edema. Ophthalmic Surg Lasers
420 Imaging Retina 50:e266-e273, 2019
421 55.Gella L, Raman R, Kulothungan V, Sharma T: Prevalence of posterior vitreous
422 detachment in the population with type II diabetes mellitus and its effect on diabetic
423 retinopathy: Sankara Nethralaya Diabetic Retinopathy Epidemiology and Molecular
424 Genetic Study SN-DREAMS report no. 23. Jpn J Ophthalmol 56:262-267, 2012
425 56.Jonas JB, Jonas RA, Neumaier M, Findeisen P: Cytokine concentration in aqueous
426 humor of eyes with diabetic macular edema. Retina 32:2150-2157, 2012
427 57.Zhu D, Yang DY, Guo YY, et al.: Intracameral interleukin 1beta, 6, 8, 10, 12p, tumor
428 necrosis factor alpha and vascular endothelial growth factor and axial length in
429 patients with cataract. PLoS One 10:e117777, 2015
430 58.Chen W, Guan Y, He G, et al.: Aqueous Levels of Pigment Epithelium-Derived
431 Factor and Macular Choroidal Thickness in High Myopia. J Ophthalmol 2015:731461,
432 2015
433 59.Ogata N, Imaizumi M, Miyashiro M, et al.: Low levels of pigment
434 epithelium-derived factor in highly myopic eyes with chorioretinal atrophy. Am J
435 Ophthalmol 140:937-939, 2005
436 60.Ganesan S, Raman R, Reddy S, et al.: Prevalence of myopia and its association
437 with diabetic retinopathy in subjects with type II diabetes mellitus: A
438 population-based study. Oman J Ophthalmol 5:91-96, 2012
439 61.Jiang J, Li X, Yuan L, et al.: Ocular biological structures and relevant risk factors in
440 the occurrence of diabetic retinopathy in diabetes mellitus patients. Chinese Journal
441 of Ophthalmology 48:898-902, 2012
442

443 **Table 1.** Previous studies investigating the influence of refractive errors on risk of diabetic retinopathy.

Study	Design	Ethnicity	No.	Exposure	Multi-adjusted associations
Moss (1994) ¹⁸	PBS, cohort	Mixed	1780	Myopia vs Emmetropia	OR=0.97 (0.39–2.41) for any DR OR=0.76 (0.28–2.02) for DR progression
Lim (2010) ¹²	PBS, CS	Malay	629	Mild myopia vs Emmetropia	OR=0.66 (0.45–0.95) for any DR OR=0.44 (0.18–1.12) for VTDR
Man (2012) ¹³	HBS, CS	Caucasian	367	Myopia vs Emmetropia	OR=0.66 (0.40–1.09) for any DR
Man (2019) ²⁰	PBS, cohort	Malay/India	840	Myopia vs Hyperopia	RR=1.08 (0.64–1.84) for any DR RR=0.83 (0.10–6.98) for VTDR RR=0.50 (0.24–1.03) for DR progression
He (2017) ²⁶	PBS, CS	Chinese	2057	Mild myopia vs Emmetropia	OR=0.68 (0.49–0.93) for any DR OR=1.36 (0.87–2.13) for VTDR
Chao (2016) ¹⁶	PBS, CS	Korean	13424	Mild myopia vs Emmetropia	OR=0.42 (0.18–0.97) for any DR
Pan (2013) ¹⁹	PBS, CS	India	3400	Mild myopia vs Emmetropia	OR=0.75 (0.50–1.13) for any DR OR=0.93 (0.40–2.14) for VTDR
Ganesan (2012) ⁶⁰	PBS, CS	India	1058	Mild myopia vs Emmetropia	OR=1.21 (0.71–2.07) for any DR OR=2.39 (0.75–7.68) for VTDR
Lim (2010) ¹²	PBS, CS	Malay	629	Moderate myopia vs Emmetropia	OR=0.59 (0.32–1.07) for any DR
He (2017) ²⁶	PBS, CS	Chinese	2057	Moderate myopia vs Emmetropia	OR=0.75 (0.49–1.14) for any DR OR=0.53 (0.21–1.32) for VTDR
Pan (2013) ¹⁹	PBS, CS	India	3400	Moderate myopia vs Emmetropia	OR=0.57 (0.27–1.20) for any DR OR=0.82 (0.20–3.32) for VTDR
Ganesan (2012) ⁶⁰	PBS, CS	India	1058	Moderate myopia vs Emmetropia	OR=1.49 (0.40–5.56) for any DR
He (2017) ²⁶	PBS, CS	Chinese	2057	High myopia vs Emmetropia	OR=0.85 (0.60–1.21) for any DR OR=1.04 (0.62–1.77) for VTDR
Pan (2013) ¹⁹	PBS, CS	India	3400	High myopia vs Emmetropia	OR=0.39 (0.12–1.24) for any DR

Ganesan (2012) ⁶⁰	PBS, CS	India	1058	High myopia vs Emmetropia	OR=1.36 (0.25–7.43) for VTDR
Chao (2016) ¹⁶	PBS, CS	Korean	13424	High myopia vs Emmetropia	OR=0.12 (0.01–1.19) for any DR
Man (2019) ²⁰	PBS, cohort	Malay/India	840	SE (per 1-D increase)	OR=0.14 (0.02–0.88) for any DR
					RR=1.11 (0.96–1.29) for any DR
					RR=0.96 (0.42–2.18) for VTDR
					RR=0.82 (0.63–1.06) for DR progression
He (2017) ²⁶	PBS, CS	Chinese	2057	SE (per 1-D increase)	OR=1.08 (1.03–1.13) for any DR
					OR=1.02 (0.96–1.09) for VTDR
Chao (2016) ¹⁶	PBS, CS	Korean	13424	SE (per 1-D increase)	OR=1.30 (1.08–1.58) for any DR
Xu (2014) ¹⁷	PBS, cohort	Chinese	2602	SE (per 1-D increase)	OR=1.12 (1.00–1.26) for any DR
Pan (2013) ¹⁹	PBS, CS	India	3400	SE (per 1-D increase)	OR=1.14 (1.05–1.23) for any DR
					OR=1.15 (0.94–1.39) for VTDR
Lim (2010) ¹²	PBS, CS	Malay	629	SE (per 1-D increase)	OR=0.90 (0.84–0.96) for any DR
					OR=0.77 (0.67–0.88) for VTDR

444 HBS= hospital-based study; PBS=population-based study; CS=cross-sectional; SE=spherical equivalent; DR=diabetic retinopathy;

445 VTDR=vision-threatening DR.

446 Bold indicates statistical significance.

447

448

449

450 **Table 2.** Summary of studies evaluating the associations of AL and AL/CR ratio with diabetic retinopathy.

Study	Design	Ethnicity	No.	Exposure	Multi-adjusted associations
Jiang (2012) ⁶¹	HBS, Case-control	Chinese	168	AL (per 1-mm increase)	OR=1.36 (0.98–1.88) for any DR
Yang (2012) ²¹	HBS, Cross-sectional	Chinese	166	AL (per 1-mm increase)	OR=0.93 (0.71–1.21) for any DR OR=0.61 (0.39–0.94) for VTDR
Man (2012) ¹³	HBS, Cross-sectional	Caucasian	367	AL (per 1-mm increase)	OR=0.76 (0.63–0.90) for any DR OR=0.74 (0.62–0.89) for DME
Xu (2014) ¹⁷	PBS, Cohort, 10 yrs	Chinese	2602	AL (per 1-mm increase)	OR=0.48 (0.33–0.71) for any DR
Man (2019) ²⁰	PBS, Cohort, 6 yrs	Malay/India	840	AL (per 1-mm increase)	RR=0.58 (0.38–0.88) for any DR RR=0.53 (0.11–2.70) for VTDR RR=0.99 (0.55–1.80) for DR progression
He (2017) ²⁶	PBS, Cross-sectional	Chinese	2057	AL (per 1-mm increase) AL/CR ratio	OR=0.88 (0.81–0.95) for any DR OR=0.93 (0.83–1.05) for VTDR OR=0.43 (0.24–0.78) for any DR OR=0.72 (0.33–1.58) for VTDR
Pan (2013) ¹⁹	PBS, Cross-sectional	India	3400	AL (per 1-mm increase)	OR=0.73 (0.63–0.86) for any DR OR=0.73 (0.49–1.09) for VTDR
Wang (2019) ²⁴	PBS, Cross-sectional	Chinese	1096	AL (per 1-mm increase)	OR=0.81 (0.70–0.95) for any DR
Lim (2010) ¹²	PBS, Cross-sectional	Malay	629	AL (per 1-mm increase)	OR=0.86 (0.75–0.99) for any DR OR=0.63 (0.40–0.99) for VTDR
Bikbov (2019) ²⁷	PBS, Cross-sectional	Caucasian	5899	AL (per 1-mm increase)	P=0.26 for any DR
Ganesan (2012) ⁶⁰	PBS, Cross-sectional	India	1058	AL (Quartile 4 vs 1)	OR=0.90 (0.54–1.50) for any DR OR=1.00 (0.31–3.22) for VTDR

451 HBS= hospital-based study; PBS=population-based study; AL=axial length; DR=diabetic retinopathy; VTDR=vision-threatening DR; AL/CR=
452 AL-to-corneal radius ratio; DME=diabetic macular edema. Bold indicates statistical significance.

453

454 **Table 3.** Relationship between the corneal curvature, anterior chamber depth, lens parameters, and diabetic retinopathy.

Study	Design	Ethnicity	No.	Multi-adjusted associations
Corneal curvature				
Man (2019) ²⁰	PBS, cohort	Malay/India	840	RR=0.33 (0.11–1.01) for any DR RR=0.12 (0.00–6.55) for VTDR RR=0.65 (0.14–3.03) for DR progression
Man (2012) ¹³	HBS, CS	Caucasian	367	OR=1.62 (0.76–3.48) for any DR
Jiang (2012) ⁶¹	HBS, case-control	Chinese	168	OR=1.01 (0.98–1.04) for any DR
Lens power				
He (2017) ²⁶	PBS, CS	Chinese	2057	OR=1.37 (0.99–1.89) for any DR OR=1.01 (0.93–1.09) for VTDR
Lens thickness				
Xu (2014) ¹⁷	PBS, cohort	Chinese	2602	OR=1.23 (0.65–2.30) for any DR
Pierro (1996) ²⁹	HBS, CS	Caucasian	57	P<0.05 for proliferative DR
Anterior chamber depth				
Man (2019)	PBS, cohort	Malay/India	840	RR=1.21 (0.63–2.34) for any DR RR=0.31 (0.06–1.75) for VTDR RR=1.85 (0.84–4.07) for DR progression
Xu (2014) ¹⁷	PBS, cohort	Chinese	2602	OR=1.33 (0.94–1.88) for any DR
Jiang (2012) ⁶¹	HBS, case-control	Chinese	168	OR=5.96 (1.78–3.81) for any DR
Lim (2010) ¹²	HBS, CS	Malay	629	OR=0.73 (0.49–1.07) for any DR OR=0.14 (0.06–0.36) for VTDR

455 HBS= hospital-based study; PBS=population-based study; AL=axial length; DR=diabetic retinopathy; VTDR=vision-threatening DR.

456 Bold indicates statistical significance.